PALO ALTO, Calif., Aug. 8, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Wedbush PacGrow Healthcare Conference in New York, NY on Wednesday, August 14 at 10:20 a.m. Eastern Time. A live webcast … Continued
– Antibody Biopolymer Conjugates are a new scientific approach and design platform for ophthalmic intravitreal drugs – KSI-301 continues to achieve its development goals of demonstrating efficacy and safety in serious retinal vascular diseases – Additional efficacy and durability data to be presented at the American Academy of Ophthalmology Retina Subspecialty Day in October 2019 … Continued
— Initial Phase 1b data for KSI-301 in Wet AMD, DME, and RVO to be presented — PALO ALTO, Calif., July 24, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that data from the ongoing KSI-301 clinical study … Continued
May 9, 2019 PALO ALTO, Calif., May 9, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV on Wednesday, May 15, … Continued
March 28, 2019 PALO ALTO, Calif., March 28, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, reported business highlights and financial results for the fourth quarter and full year ended December 31, 2018. “The fourth quarter of 2018 capped an exciting … Continued
Palo Alto, CA — March 7, 2019 – Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Barclays Global Healthcare Conference in Miami Beach, FL on Tuesday, March 12 at 1:35 p.m. Eastern Time. A live … Continued
February 8, 2019 PALO ALTO, Calif., Feb. 8, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that a presentation on its investigational therapy KSI-301 will be made at the Angiogenesis, Exudation, and Degeneration 2019 meeting being held on … Continued
PALO ALTO, Calif., Dec. 24, 2018 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it has been added to the Russell 2000®, 3000® and Microcap® Indexes, effective as of the open of the U.S. markets on Monday, December … Continued
December 21, 2018 — Rapid high-magnitude and durable treatment responses were seen at all dose levels tested in a heavily pre-treated Phase 1 patient population. — Twelve weeks after a single dose, median vision improvement from baseline of almost two lines of vision (9 eye chart letters) and median improvement in retinal edema of 121 … Continued
Palo Alto, CA, November 16, 2018 – Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the third quarter ended September 30, 2018. “The successful first dosing of patients with KSI-301, our novel antibody biopolymer conjugate, … Continued